Table 2.
Baseline clinical characteristics at diagnosis of localised or metastatic disease.
| Localised disease (N = 30) | Metastatic disease (N = 20) | |
|---|---|---|
| Median age (SD) | 43 (18.5) | 49 (21.1) |
|
| ||
| Sex | ||
| Female | 14 | 11 |
| Male | 16 | 9 |
|
| ||
| Median tumour size, cm (range) | 6 (1–27) | 10 (4–30) |
|
| ||
| Anatomical location of the primary tumour | ||
| Head and neck (nonparameningeal and parameningeal) | 4 | ≤ 2∗ |
| Intrathoracic, abdominal, and retroperitoneal organs | 7 | 7 |
| Extremities | 14 | 10 |
| Genitourinary | 5 | NA∗ |
|
| ||
| Site∗∗ | ||
| Unfavourable | 22 | 18 |
| Favourable | 7 | NA∗ |
|
| ||
| Metastatic site | ||
| Lung | 0 | 9 |
| Liver | 0 | ≤ 2∗ |
| Bone | 0 | ≤ 2∗ |
| Others | 0 | 8 |
|
| ||
| Treatment intent | ||
| Curative | 13 | 9 |
| Palliative | 5 | 6 |
Site: favourable sites are GU including bladder prostate, head and neck nonparameningeal, orbit, and biliary primaries; unfavourable sites are all other sites including NOS and extremities [8]. Histologic subtype: favourable: embryonal; unfavourable: alveolar, pleomorphic, and not otherwise specified [2]. ∗According to the Danish law, it is not legal to report on individual patients without the patients' signed consent. Therefore, if a cell includes ≤ 2 patients, the cells with the lowest number of patients have been blinded.